Filing Flows › Viridian Therapeutics (VRDN) › Q2 2026
Viridian Therapeutics (VRDN) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Viridian Therapeutics (VRDN) reported revenue of $284K for the second quarter 2026 (Q2 2026), +279% from a year earlier and +101% from the quarter before.
Viridian Therapeutics, Q2 2026: revenue $284K (+279% year over year), net loss $127M, operating cash flow −$105M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $284K | +101% | +279% |
| Operating profit | −$126M | — | — |
| Net earnings | −$127M | — | — |
| Operating cash flow | −$105M | — | — |
What changed
Revenue was $284K in Q2 2026, up 279% year over year and up 101% from the previous quarter.
Operating costs exceeded revenue by $126.3M, an operating margin of -44460.6%. Total costs grew 18% against revenue growth of 279%. The fastest-growing cost line was SG&A (+172%). The quarter ended with a net loss of $127.1M, wider than the previous quarter's $104.9M loss.
Operating cash flow was −$105.3M. Non-cash charges added back $117K of depreciation and amortization and $17.0M of share-based compensation. Capital expenditures of $1.3M exceeded it, leaving free cash flow of −$106.6M.
Questions
What was Viridian Therapeutics' revenue in the second quarter 2026?
Viridian Therapeutics (VRDN) reported revenue of $284K for the second quarter 2026 (Q2 2026), +279% from a year earlier and +101% from the quarter before.